Distribution agreement signed for the French market

Hemcheck Sweden AB has signed a three-year distribution agreement with Eurobio Scientific, a leading distributor and manufacturer of medical equipment based in France, with operations across several other countries such as the US, Germany, and UK.

– Eurobio Scientific is a large company and a well-established distributor in France with a focus on e.g., IVD and quality control that fits Hemcheck very well. We hope that the collaboration will be successful and look forward to starting the work together, says Joen Averstad, CEO of Hemcheck.

– We are very happy with signing this agreement with Hemcheck. We believe the products have good potential in the French market and we look forward to starting the sales and marketing work, says Jean-Michel Carle, CEO at Eurobio Scientific. 

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Eurobio Scientific

The Eurobio Scientific group is a French fully integrated leader in the field of in vitro diagnostics with expertise ranging from discovery to commercialization of specialty diagnostic solutions as well as products for research in life-science. Eurobio Scientific owns a broad and diversified portfolio of proprietary products in four specialty areas: transplantation, infectious diseases, life-science and cancer. Under exclusivity, Eurobio Scientific also commercializes tests and automated solutions developed by foreign industrial partners in the field of infectious diseases, auto-immunity and quality control. It also sells a comprehensive range of reagents and instruments to life-science R&D laboratories.

Read more at: https://eurobio-scientific.eu/fr/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.